New York, USA-based provider of an end-to-end platform for vaccine automation and management, Canid raised USD 1.5 million in funding. The round took place on September 21, 2023. SeedtoB Capital, an early-stage fund focused on healthcare innovation and artificial intelligence, led the financing for the firm. Meanwhile, FJ Labs, Alumni Ventures, I2BF and MKT1 joined in the funding.
Purpose of financing for Canid
With the latest funding, Canid has plans to expand its geographic footprint to 10 new states across the U.S.A. It also intends to add new tools to manage vaccine patient populations.
What the company’s official has to add
Pedro Sanchez de Lozada, founder and CEO of Canid, said, “Vaccinations have been taken for granted for decades. They’re the #1 most valuable public health tool we have as a society, and yet they’re always the last priority for our healthcare system. We’re at a point where doctors and patients alike see vaccines as a burden instead of the life-saving preventative care interventions that they are. Our goal at Canid is to change that. By eliminating the burden of giving and receiving vaccines, we hope to make it exciting again to take part. This starts at the doctor’s office, where a typical paediatrician’s office will give vaccines to hundreds of kids per day.”
SeedtoB Capital invests in early-stage businesses, driving the adoption of innovative technology within the healthcare ecosystem. Ritesh Sharma and Shantanu Nigam are the founders of the company.
What the investors have to comment
Ritesh Sharma, Managing Partner at SeedtoB Capital, said, “Canid is currently live in 4 states, 3 of which have been added in the past quarter. We’re excited to support Pedro and the team to expand across the Southwest and Midwest United States to meet the demand for a new way to vaccinate. As Canid works with larger and larger swaths of the population country-wide, new tools enabling the company to improve vaccination rates will be critical to expanding the impact of their methodology.”
About Canid
In 2020, Founder Pedro Sanchez de Lozada launched the company. Canid operates as an end-to-end vaccine workflow automation and management solution. It allows practices to more effectively manage the purchasing, delivery, as well as record management of vaccines. It further eliminates the administrative complexity of vaccine delivery. In addition, Canid empowers clinicians to deliver higher-quality care and ultimately drive improvements in public health.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
